Rock Springs Capital Management LP Sells 42,268 Shares of Celldex Therapeutics, Inc. $CLDX

Rock Springs Capital Management LP trimmed its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 6.1% in the 1st quarter, HoldingsChannel reports. The firm owned 650,270 shares of the biopharmaceutical company’s stock after selling 42,268 shares during the period. Celldex Therapeutics makes up 1.2% of Rock Springs Capital Management LP’s portfolio, making the stock its 25th largest holding. Rock Springs Capital Management LP’s holdings in Celldex Therapeutics were worth $20,627,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. Wilmington Savings Fund Society FSB purchased a new position in Celldex Therapeutics during the third quarter valued at $42,000. Russell Investments Group Ltd. increased its position in Celldex Therapeutics by 27.6% in the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 501 shares in the last quarter. Quantbot Technologies LP bought a new position in shares of Celldex Therapeutics in the third quarter worth about $63,000. Kestra Advisory Services LLC bought a new position in shares of Celldex Therapeutics in the fourth quarter worth about $98,000. Finally, Headlands Technologies LLC bought a new position in shares of Celldex Therapeutics in the second quarter worth about $125,000.

Celldex Therapeutics Stock Up 1.0%

NASDAQ:CLDX opened at $35.65 on Tuesday. The business’s 50-day simple moving average is $33.75 and its two-hundred day simple moving average is $30.78. Celldex Therapeutics, Inc. has a 52 week low of $19.72 and a 52 week high of $40.30. The stock has a market cap of $2.80 billion, a PE ratio of -8.37 and a beta of 0.90.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.03). The firm had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.80 million. Sell-side analysts anticipate that Celldex Therapeutics, Inc. will post -4.36 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on CLDX shares. Barclays boosted their price objective on Celldex Therapeutics from $45.00 to $48.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Celldex Therapeutics in a research note on Friday, July 17th. Wall Street Zen raised shares of Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, July 12th. Wells Fargo & Company dropped their price target on shares of Celldex Therapeutics from $54.00 to $48.00 and set an “overweight” rating for the company in a research report on Wednesday, July 22nd. Finally, Morgan Stanley dropped their price target on shares of Celldex Therapeutics from $44.00 to $40.00 and set an “overweight” rating for the company in a research report on Wednesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $52.77.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.